NEW YORK, March 15, 2019 /PRNewswire/ -- WeissLaw
LLP is investigating possible breaches of fiduciary duty
and other violations of law by the Board of Directors of Osiris
Therapeutics, Inc. ("OSIR" or the "Company") (NASDAQ: OSIR) in
connection with the proposed acquisition of the Company by Smith
& Nephew plc ("SNN"). Under the terms of the acquisition
agreement, shareholders will receive $19.00 in cash for each OSIR share they own.
If you own OSIR shares and wish to discuss
this investigation or have any questions
concerning this notice or your rights or interests, please
contact:
Joshua Rubin,
Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY 10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com
Visit our website
http://www.weisslawllp.com/osiris-therapeutics-inc/
Or follow us on Twitter @MarketsAlert
WeissLaw is investigating whether OSIR's Board acted to maximize
shareholder value prior to entering into the agreement.
Notably, according to SNN's CEO, the acquisition of OSIR will:
- Enhance SNN's presence in the rapidly growing regenerative
medicine market;
- Expand SNN's portfolio;
- Accelerate SNN's wound management business; and
- Enable longer term innovations in additional channels.
Moreover, OSIR reported revenue growth of 18.7% and 22.4% for
the three-month, and the nine-month periods ended September 30, 2018, respectively.
Given these facts, WeissLaw is concentrating its investigation
on whether OSIR's Board conducted a fair process in agreeing to the
proposed acquisition, whether the proposed acquisition undervalues
the Company, and whether all material information related to the
proposed acquisition is fully and fairly disclosed.
WeissLaw LLP has litigated hundreds of stockholder class and
derivative actions for violations of corporate and fiduciary
duties. We have recovered over a billion dollars for
defrauded clients and obtained important corporate governance
relief in many of these cases. If you have information or
would like legal advice concerning possible corporate wrongdoing
(including insider trading, waste of corporate assets, accounting
fraud, or materially misleading information), consumer fraud
(including false advertising, defective products, or other
deceptive business practices), or anti-trust violations, please
email us at stockinfo@weisslawllp.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-osiris-therapeutics-inc-300813425.html
SOURCE WeissLaw LLP